TERT C228T MUTATION IN CIRCULATING TUMOR DNA AS A CLINICAL MARKER IN HEPATOCELLULAR CARCINOMA PATIENTS ATTENDING A TERTIARY HOSPITAL IN EGYPT: A CASE-CONTROL STUDY
Ismaeil, K., Abdelhakam, D., Montasser, I., Kassem, P., Ahmed, R., Fathi, M. (2023). TERT C228T MUTATION IN CIRCULATING TUMOR DNA AS A CLINICAL MARKER IN HEPATOCELLULAR CARCINOMA PATIENTS ATTENDING A TERTIARY HOSPITAL IN EGYPT: A CASE-CONTROL STUDY. EKB Journal Management System, 74(2), 413-422. doi: 10.21608/asmj.2023.307108
Khaled Mohy Ismaeil Abdelrehim Ismaeil; Dina Abdelmoneim Mahmoud Abdelhakam; Iman Fawzy Montasser; Perihan Hamdy Kassem; Ramy Mohamed Mahmoud Ahmed; Marium El Sayed Ahmed Fathi. "TERT C228T MUTATION IN CIRCULATING TUMOR DNA AS A CLINICAL MARKER IN HEPATOCELLULAR CARCINOMA PATIENTS ATTENDING A TERTIARY HOSPITAL IN EGYPT: A CASE-CONTROL STUDY". EKB Journal Management System, 74, 2, 2023, 413-422. doi: 10.21608/asmj.2023.307108
Ismaeil, K., Abdelhakam, D., Montasser, I., Kassem, P., Ahmed, R., Fathi, M. (2023). 'TERT C228T MUTATION IN CIRCULATING TUMOR DNA AS A CLINICAL MARKER IN HEPATOCELLULAR CARCINOMA PATIENTS ATTENDING A TERTIARY HOSPITAL IN EGYPT: A CASE-CONTROL STUDY', EKB Journal Management System, 74(2), pp. 413-422. doi: 10.21608/asmj.2023.307108
Ismaeil, K., Abdelhakam, D., Montasser, I., Kassem, P., Ahmed, R., Fathi, M. TERT C228T MUTATION IN CIRCULATING TUMOR DNA AS A CLINICAL MARKER IN HEPATOCELLULAR CARCINOMA PATIENTS ATTENDING A TERTIARY HOSPITAL IN EGYPT: A CASE-CONTROL STUDY. EKB Journal Management System, 2023; 74(2): 413-422. doi: 10.21608/asmj.2023.307108

TERT C228T MUTATION IN CIRCULATING TUMOR DNA AS A CLINICAL MARKER IN HEPATOCELLULAR CARCINOMA PATIENTS ATTENDING A TERTIARY HOSPITAL IN EGYPT: A CASE-CONTROL STUDY

Ain Shams Medical Journal
Volume 74, Issue 2, June 2023, Page 413-422  XML PDF (446.75 K)
Document Type: Original Article
DOI: 10.21608/asmj.2023.307108
View on SCiNiTO View on SCiNiTO
Authors
Khaled Mohy Ismaeil Abdelrehim Ismaeil email 1; Dina Abdelmoneim Mahmoud Abdelhakam1; Iman Fawzy Montasser2; Perihan Hamdy Kassem1; Ramy Mohamed Mahmoud Ahmed1; Marium El Sayed Ahmed Fathiorcid 1
1Clinical Pathology, Faculty of Medicine Ain Shams University, Cairo, Egypt.
2Tropical Medicine departments, Faculty of Medicine Ain Shams University, Cairo, Egypt.
Abstract
Background: Diagnosis of hepatocellular carcinoma (HCC) by liver biopsy can be challenging due to limited liver access and cirrhosis. Circulating tumor DNA (ctDNA) are genetic fragments originating from the tumor that circulate as a part of circulating free DNA and offer a representative sample of the tumor molecular profile.
Aim of work: Our study aimed to investigate the role of TERT C228T promoter mutation in ctDNA as a diagnostic biomarker in Egyptian HCC patients. Methods: Our study is a case-control study that included 16 advanced HCC (AHCC), 12 early HCC (EHCC) cases, 10 chronic hepatitis C virus (HCV) patients as pathological control group and 10 healthy controls. Plasma was collected for genotyping of TERT C228T promoter mutation by real-time PCR. Results: All cases in our study including AHCC and EHCC patients as well as HCV pathological controls and healthy controls carried the wild TERT genotype. There was a significant difference of AST, ALT, total bilirubin and albumin between the different groups included in the study. Our study has also shown that AFP levels were significantly higher in AHCC patients when compared to EHCC patients. Conclusion: All studied samples in our study had the wild TERT genotype in ctDNA by real-time PCR. This could be attributed to the relatively small sample size of our study, and the relatively lower sensitivity of real-time PCR compared to other technologies such as droplet digital PCR (ddPCR) or next-generation sequencing. Future studies should include a larger sample size and utilize more sensitive technologies.
Keywords
Hepatocellular Carcinoma; Molecular Markers; TERT; ctDNA
Statistics
Article View: 209
PDF Download: 142